Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease

Am J Cardiol. 2005 Jun 15;95(12):1456-9. doi: 10.1016/j.amjcard.2005.02.013.

Abstract

The long-term beneficial effects of placebo therapy were evaluated in angiogenesis and laser myocardial revascularization trials in patients who had end-stage coronary heart disease. Improvements in mean angina class, exercise treadmill time, and quality of life were mostly maintained at 30 +/- 6 months of follow-up. Persistence of effect cannot be used as evidence of efficacy, and double-blinded trials are essential in this patient population.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Angioplasty, Laser
  • Anticoagulants / administration & dosage
  • Anticoagulants / therapeutic use
  • Coronary Disease / diagnosis
  • Coronary Disease / drug therapy*
  • Coronary Disease / surgery*
  • Double-Blind Method
  • Exercise Test
  • Exercise Tolerance / physiology
  • Female
  • Fibroblast Growth Factor 2 / administration & dosage
  • Fibroblast Growth Factor 2 / therapeutic use*
  • Follow-Up Studies
  • Heparin / administration & dosage
  • Heparin / therapeutic use
  • Humans
  • Infusions, Intravenous
  • Male
  • Myocardial Revascularization / methods*
  • Placebo Effect
  • Randomized Controlled Trials as Topic* / methods
  • Recombinant Proteins / therapeutic use
  • Severity of Illness Index
  • Time Factors
  • Treatment Outcome

Substances

  • Anticoagulants
  • Recombinant Proteins
  • Fibroblast Growth Factor 2
  • Heparin